BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 32429739)

  • 1. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
    Ud Din N; Umer M; Park YK
    Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
    [No Abstract]   [Full Text] [Related]  

  • 2. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
    Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
    J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists.
    Tariq MU; Umer M; Khan Z; Saeed J; Siddiqui MA; Din NU
    Ann Diagn Pathol; 2020 Apr; 45():151479. PubMed ID: 32088577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
    Yamamoto H; Ishihara S; Toda Y; Oda Y
    Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
    Yang L; Zhang H; Zhang X; Tang Y; Wu Z; Wang Y; Huang H; Fu X; Liu J; Hogendoorn PCW; Cheng H
    Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical Characterization of Giant Cell Tumor of Bone Treated With Denosumab: Support for Osteoblastic Differentiation.
    Kerr DA; Brcic I; Diaz-Perez JA; Shih A; Wilky BA; Pretell-Mazzini J; Subhawong TK; Nielsen GP; Rosenberg AE
    Am J Surg Pathol; 2021 Jan; 45(1):93-100. PubMed ID: 32773532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
    Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
    Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
    Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.
    Yamamoto H; Iwasaki T; Yamada Y; Matsumoto Y; Otsuka H; Yoshimoto M; Kohashi K; Taguchi K; Yokoyama R; Nakashima Y; Oda Y
    Hum Pathol; 2018 Mar; 73():41-50. PubMed ID: 29241742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Histone H3.3 G34W antibody is a sensitive and highly specific immunohistochemistry marker for the diagnosis of Giant cell tumor of bone. A validation based on analysis of 198 cases from a single centre in India.
    Kamble A; Hui M; Rao KN; Narayanan R; Reddy BR; Uppin SG; Chandrasekhar P
    Indian J Pathol Microbiol; 2022; 65(3):617-629. PubMed ID: 35900490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological Features of a Series of 27 Cases of Post-Denosumab Treated Giant Cell Tumors of Bones: A Single Institutional Experience at a Tertiary Cancer Referral Centre, India.
    Rekhi B; Verma V; Gulia A; Jambhekar NA; Desai S; Juvekar SL; Bajpai J; Puri A
    Pathol Oncol Res; 2017 Jan; 23(1):157-164. PubMed ID: 27722984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
    Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
    Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
    Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
    Scoccianti G; Totti F; Scorianz M; Baldi G; Roselli G; Beltrami G; Franchi A; Capanna R; Campanacci DA
    Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
    Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
    World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of RANKL Expression in Osteocyte-like Differentiated Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment.
    Noguchi T; Sakamoto A; Murotani Y; Murata K; Hirata M; Yamada Y; Toguchida J; Matsuda S
    J Histochem Cytochem; 2023 Mar; 71(3):131-138. PubMed ID: 36971322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab Induces Neoplastic Stromal Cell Apoptosis
    Chen X; Ye F; He H; Chen G; Chen Z; Ye E; He B; Yang Y; Zhang J
    Curr Cancer Drug Targets; 2024; 24(5):565-578. PubMed ID: 37961860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An eggshell-like mineralized recurrent lesion in the popliteal region after treatment of giant cell tumor of the bone with denosumab.
    Akaike K; Suehara Y; Takagi T; Kaneko K; Saito T
    Skeletal Radiol; 2014 Dec; 43(12):1767-72. PubMed ID: 25052539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab.
    Mukaihara K; Suehara Y; Kohsaka S; Akaike K; Tanabe Y; Kubota D; Ishii M; Fujimura T; Kazuno S; Okubo T; Takagi T; Yao T; Kaneko K; Saito T
    PLoS One; 2016; 11(2):e0148401. PubMed ID: 26863138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
    Agarwal MG; Gundavda MK; Gupta R; Reddy R
    Clin Orthop Relat Res; 2018 Sep; 476(9):1773-1782. PubMed ID: 30794215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.